Silo Pharma Expands Agreement with Sever Pharma for Novel Ketamine Implant

Silo Pharma, Inc. (Nasdaq: SILO), a developmental stage biopharmaceutical company, has announced a new collaboration with Sever Pharma Solutions. This agreement focuses on advancing the scale-up of the company's SP-26 ketamine-loaded implant, designed to treat chronic pain and fibromyalgia. Additionally, Sever Pharma will continue performing analytical testing on the ketamine hydrochloride polymer implants using an optimal time-released, dose-controlled formulation.

Sever Pharma Solutions has previously partnered with Silo Pharma in the production and validation of these ketamine implants. Eric Weisblum, CEO of Silo Pharma, expressed his satisfaction with the ongoing collaboration, emphasizing its role in the further pre-clinical testing of their novel non-opioid chronic pain therapeutic. Weisblum believes that this process will bring Silo closer to determining the final dosage and formulation to be used in future animal studies.

SP-26, Silo’s innovative treatment, is an injectable, dissolvable polymer implant based on ketamine. It is specifically designed for the treatment of chronic pain and fibromyalgia, aiming to safely regulate both dosage and time release of the pain-relieving medication. If pre-clinical studies of SP-26 prove successful, the treatment could potentially qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval, which could expedite the process of bringing the treatment to market.

Silo Pharma Inc. is focused on developing novel therapeutic solutions for underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's approach combines traditional therapies and psychedelic treatments in innovative formulations and drug delivery systems. Silo’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. SP-26, the ketamine-loaded implant, is designed for treating fibromyalgia and chronic pain.

In addition to SP-26, Silo Pharma is working on other preclinical programs. These include SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development efforts are conducted through collaborations with various universities and independent laboratories, showcasing a robust pipeline aimed at addressing significant medical needs.

With the new agreement to scale-up the SP-26 implants, Silo Pharma aims to further enhance the development and potential approval of this non-opioid treatment for chronic pain and fibromyalgia. The continued analytical testing by Sever Pharma Solutions is expected to provide valuable data that will inform the final stages of pre-clinical development and dosage optimization.

Silo Pharma's focus on creating novel treatment options for chronic pain and other serious conditions highlights its commitment to addressing unmet medical needs. Through strategic partnerships and innovative research, the company aims to bring effective and safe therapeutic solutions to patients, potentially transforming the landscape of chronic pain management and other related disorders.